The full webinar is available here. A summary of the key discussion points follows below.
Key Takeaways
- Decoupled Onset and Survival: Research indicates that the age of onset and survival rates are decoupled in SOD1-ALS.
- Variant-Specific Trajectories: Certain SOD1 gene variants are linked to distinct survival trajectories, which can help predict disease progression.
- Data Standardization: Large, annotated clinical datasets are necessary to increase study power and improve clinical trial design.
- Family History Impact: Study findings suggest that family history does not significantly affect the age of onset or disease duration.
About the speakers
Paul Wicks, PhD
Paul Wicks is a consultant to clinical research and digital therapeutics companies, including Sano Genetics, Ada Health, and Woebot Health. Paul spent over a decade at PatientsLikeMe, progressing from R&D into the role of VP of Innovation.
Dr. Sarah Opie-Martin
Dr. Sarah Opie-Martin is a data scientist specializing in ALS research, with expertise in medical statistics, database design, and large-scale clinical data analysis. Her PhD in Clinical Neuroscience focused on cleaning and analyzing large clinical datasets to better characterize disease progression. She brings a strong background in clinical audit, guidelines development, and programming applied to medical research.
Highlights from the webinar
How does age of onset relate to disease progression in SOD1-ALS?
The short answer from Dr. Opie-Martin's research: no, age of onset does not reliably predict the speed of progression in SOD1-ALS. Her study demonstrated that onset and survival are decoupled, meaning that knowing when a patient first develops symptoms does not tell you how quickly the disease will advance. This contrasts with patterns seen in sporadic ALS, where earlier onset is sometimes associated with slower progression.
Critically, certain SOD1 variants are associated with distinct survival trajectories. This variant-level heterogeneity has direct implications for clinical trial design. If patients carrying different variants follow fundamentally different disease courses, grouping them together without stratification introduces variability that can obscure treatment effects.
To address this, the research aims to build a large, annotated clinical dataset of people with SOD1-ALS. By classifying variants and grouping them by progression profile, researchers can increase statistical power and reduce noise. For sponsors designing genetically stratified trials, this kind of variant annotation is essential for setting realistic enrollment targets, defining appropriate endpoints, and ensuring that trial populations are sufficiently homogeneous to detect a signal.
What are the challenges of reconciling multi-country SOD1-ALS datasets?
The webinar explored the challenges of reconciling datasets from multiple countries, each with different clinical definitions and varying levels of detail. In SOD1-ALS research, this is a persistent problem. Family history definitions differ across registries, diagnostic criteria vary between healthcare systems, and the depth of clinical annotation is inconsistent.
These inconsistencies make it difficult to draw reliable statistical inferences from pooled data. This matters because SOD1 mutations appear across both familial ALS (10–20% of cases) and sporadic ALS (1–2% of cases), meaning that datasets necessarily span different clinical contexts and geographies.
One notable finding from Dr. Opie-Martin's study was that family history did not affect the age of onset or disease duration. This is a meaningful result for trial design, as it indicates that patients with and without a known family history of ALS can be grouped together in analyses without introducing a confounding variable. For sponsors planning multi-country enrollment programs, this kind of clarity around covariates directly informs eligibility criteria and stratification decisions.
Summary
This webinar examined how variant-level data in SOD1-ALS can reshape assumptions about disease progression and inform more precise trial design. The core finding, that age of onset and survival are decoupled, and that specific variants follow distinct trajectories, has direct consequences for how sponsors stratify patients, define endpoints, and forecast enrollment.
Since this research was presented, the SOD1-ALS landscape has continued to evolve. The FDA approval of tofersen (Qalsody) under the accelerated approval pathway validated the use of neurofilament light (NfL) as a surrogate biomarker for treatment effect. The ongoing ATLAS trial is now testing whether tofersen can delay symptom onset in presymptomatic SOD1 mutation carriers, marking a shift toward disease prevention rather than treatment alone.
For sponsors and clinical teams working in genetically defined populations, these developments underscore a broader point: understanding variant-level biology is no longer optional. It is the foundation for designing trials that can detect meaningful effects in small, heterogeneous populations.
Watch the full webinar here.